on Nanohale AG (isin : DE000A1EWVY8)
Bio Usawa to Commercialize FYB201 in Sub-Saharan Africa
Bioeq AG, holder of commercialization rights for FYB201, has partnered with Bio Usawa Biotechnology Ltd. for the distribution of FYB201/BioUcenta™ (ranibizumab) in Sub-Saharan Africa. This strategic move significantly expands the reach of this monoclonal antibody used to treat retinal diseases such as diabetic macular edema.
The drug is already established in high-income countries, but has been inaccessible for much of Africa due to high costs. The partnership aims for a product launch in early 2026, offering a crucial treatment option for millions threatened by diabetes-related blindness.
Dr. Menghis Bairu, CEO of Bio Usawa, emphasizes the collaboration's goal of equitable access to advanced biologic therapies. Formycon AG also highlights this as a step towards democratizing biotherapies for developing regions.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news